Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Gamma for MDRTB
NCT00001407Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 1994
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of interferon gamma-1b in multidrug-resistant tuberculosis (MDR-TB) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Tolerance and Toxicity at 1 year and Clinical Effect (Sputum Culture Conversion) at 1 year. Started May 1994; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT00001407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001407.